Literature DB >> 28416348

Respiratory function in facioscapulohumeral muscular dystrophy 1.

M Wohlgemuth1, C G C Horlings2, E L van der Kooi3, H J Gilhuis4, J C M Hendriks5, S M van der Maarel6, B G M van Engelen2, Y F Heijdra7, G W Padberg2.   

Abstract

To test the hypothesis that wheelchair dependency and (kypho-)scoliosis are risk factors for developing respiratory insufficiency in facioscapulohumeral muscular dystrophy, we examined 81 patients with facioscapulohumeral muscular dystrophy 1 of varying degrees of severity ranging from ambulatory patients to wheelchair-bound patients. We examined the patients neurologically and by conducting pulmonary function tests: Forced Vital Capacity, Forced Expiratory Volume in 1 second, and static maximal inspiratory and expiratory mouth pressures. We did not find pulmonary function test abnormalities in ambulant facioscapulohumeral muscular dystrophy patients. Even though none of the patients complained of respiratory dysfunction, mild to severe respiratory insufficiency was found in more than one third of the wheelchair-dependent patients. Maximal inspiratory pressures and maximal expiratory pressures were decreased in most patients, with a trend that maximal expiratory pressures were more affected than maximal inspiratory pressures. Wheelchair-dependent patients with (kypho-)scoliosis showed the most restricted lung function. Wheelchair-dependent patients with (kypho-)scoliosis are at risk for developing respiratory function impairment. We advise examining this group of facioscapulohumeral muscular dystrophy patients periodically, even in the absence of symptoms of respiratory insufficiency, given its frequency and impact on daily life and the therapeutic consequences.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  FSHD1; Facioscapulohumeral muscular dystrophy; Pulmonary function; Respiratory muscles

Mesh:

Year:  2017        PMID: 28416348     DOI: 10.1016/j.nmd.2017.03.008

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  7 in total

Review 1.  Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments.

Authors:  Johanna Hamel; Rabi Tawil
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

2.  Transcriptional and cytopathological hallmarks of FSHD in chronic DUX4-expressing mice.

Authors:  Darko Bosnakovski; Ahmed S Shams; Ce Yuan; Meiricris T da Silva; Elizabeth T Ener; Cory W Baumann; Angus J Lindsay; Mayank Verma; Atsushi Asakura; Dawn A Lowe; Michael Kyba
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 3.  Facioscapulohumeral muscular dystrophy-Reproductive counseling, pregnancy, and delivery in a complex multigenetic disease.

Authors:  Sanne C C Vincenten; Nienke Van Der Stoep; Aimée D C Paulussen; Karlien Mul; Umesh A Badrising; Marjolein Kriek; Olivier W H Van Der Heijden; Baziel G M Van Engelen; Nicol C Voermans; Christine E M De Die-Smulders; Saskia Lassche
Journal:  Clin Genet       Date:  2021-08-01       Impact factor: 4.296

4.  Facioscapulohumeral Dystrophy in Childhood: A Nationwide Natural History Study.

Authors:  Rianne J M Goselink; Tim H A Schreuder; Nens van Alfen; Imelda J M de Groot; Merel Jansen; Richard J L F Lemmers; Patrick J van der Vliet; Nienke van der Stoep; Thomas Theelen; Nicol C Voermans; Silvère M van der Maarel; Baziel G M van Engelen; Corrie E Erasmus
Journal:  Ann Neurol       Date:  2018-10-16       Impact factor: 10.422

5.  Long-term follow-up of respiratory function in facioscapulohumeral muscular dystrophy.

Authors:  Sjan Teeselink; Sanne C C Vincenten; Nicol C Voermans; Jan T Groothuis; Jonne Doorduin; Peter J Wijkstra; Corinne G C Horlings; Baziel G M van Engelen; Karlien Mul
Journal:  J Neurol       Date:  2022-02-11       Impact factor: 4.849

Review 6.  Outcome Measures in Facioscapulohumeral Muscular Dystrophy Clinical Trials.

Authors:  Mehdi Ghasemi; Charles P Emerson; Lawrence J Hayward
Journal:  Cells       Date:  2022-02-16       Impact factor: 6.600

7.  Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit DUX4 Expression.

Authors:  Ngoc Lu-Nguyen; George Dickson; Alberto Malerba; Linda Popplewell
Journal:  Biomedicines       Date:  2022-07-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.